Inflammation of the Heart Muscle Tissue in Patients with Rheumatoid Arthritis

Overview

About this study

The purpose of this study is to determine if PET imaging in patients with rheumatoid arthritis reveals evidence of myocardial inflammation which correlates with the level of systemic inflammatory burden.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Diagnosis of Rheumatoid Arthritis according to 2010 American College of Rheumatology (ACR) criteria.
  • RA disease duration ≤ 10 years since diagnosis.
  • CDAI Score of either ≤ 2.8 (low disease activity) or >10 (moderate-to-high disease activity).
  • ≥ 40 years of age.
  • Able to provide informed consent.

Exclusion Criteria:

  • Known clinical atherosclerotic disease (myocardial infarction, severe obstruction CAD (≥ 1 untreated stenosis (≥ 70% in a major vessel) known by either invasive or noninvasive testing), prior coronary artery intervention, prior coronary artery bypass surgery, cerebrovascular event, peripheral vascular disease).
  • Prednisone >10mg per day (or equivalent corticosteroid dose per day within last week).
  • Irregular heart rhythm (arrhythmia or cardiac conduction abnormality (i.e., atrial fibrillation or flutter, frequentextrasystole, LBBB).
  • Relevant valvular heart disease (> moderate regurgitation or stenosis of any heart valve).
  • Clinical occurrence of heart failure with or without preserved ejection fraction.
  • Impaired imaging quality or others contraindications for myocardial strain imaging.
  • Relevant lung disease (including COPD, fibrosis, symptomatic pleural effusion, oxygen dependence).
  • Sarcoidosis.
  • Diabetes mellitus treated with insulin.
  • Estimated glomerular filtration rate (eGFR) < 40ml/min.
  • Known cancer.
  • History of any-type of cardiomyopathy (i.e., cardiac amyloidosis, hypertrophic cardiomyopathy ...).
  • Ejection fraction (EF) less than 45%.
  • Life expectancy < 1 year.
  • BMI > 40kg/m^2.
  • Severe claustrophobia.
  • Any known allergic reactions to intravenous contrast.
  • Inability to receive beta blocker therapy or IV nitrates.
  • Pregnant / breastfeeding women.
  • Vulnerable persons due to Helsinki Declaration.
  • Unable to provide informed consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rekha Mankad, M.D.

Open for enrollment

Contact information:

Jane McGlinch B.S.

(507)538-6123

McGlinch.Jane@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20438428

Mayo Clinic Footer